Fluocinolone acetonide SR is under clinical development by EyePoint Pharmaceuticals and currently in Phase III for Posterior Uveitis. According to GlobalData, Phase III drugs for Posterior Uveitis have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Fluocinolone acetonide SR’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Fluocinolone acetonide SR overview

Fluocinolone acetonide (Iluvien, Medidur, Yutiq) is a glucocorticoid derivative. It is formulated as an injectable, non-erodible, intravitreal implant in a 36-month sustained-release drug delivery system. It is indicated for the treatment of vision impairment associated with chronic diabetic macular edema, considered insufficiently responsive to available therapies, for the treatment of diabetic macular edema in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure, and for prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIPU). It is based on Durasert technology system and Medidur Delivery system.

Fluocinolone acetonide is under development for the treatment of posterior uveitis and retinitis pigmentosa. It was also under development for the treatment of retinal vein occlusion, geographic atrophy (an advanced form of dry age-related macular degeneration), exudative age-related macular degeneration and osteoarthritis. It was under development for the treatment of posterior uveitis (intraocular route).

EyePoint Pharmaceuticals overview

EyePoint Pharmaceuticals (EyePoint), formerly pSivida, is a biopharmaceutical company that offers development of miniaturized, sustained-release drug delivery products and technologies. The company offers products such as iluvien, retisert and durasert, among others. It is an injectable, miniaturized, sustained-release drug delivery system, used for the treatment of chronic diseases of the back of the eye. EyePoint iluvien is an injectable, non-erodible, intravitreal implant for the treatment of DME. The company provides drug delivery products and technologies to treat serious, debilitating diseases of the eye that can lead to blindness. It operates in the US and the UK. EyePoint is headquartered in Watertown, Massachusetts, the US.

For a complete picture of Fluocinolone acetonide SR’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 15 September 2023

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.